Clinical Use of Drug Delivery Systems: Prescription Survey on Clinical Use of PGE1 in Lipid Emulsions with Aqueous Infusions.

B. Hino, Y. Kurosaki, K. Yamauchi, K. Kamiya, H. Araki, Y. Gomita, N. Goto, M. Masada, H. Kawasaki
{"title":"Clinical Use of Drug Delivery Systems: Prescription Survey on Clinical Use of PGE1 in Lipid Emulsions with Aqueous Infusions.","authors":"B. Hino, Y. Kurosaki, K. Yamauchi, K. Kamiya, H. Araki, Y. Gomita, N. Goto, M. Masada, H. Kawasaki","doi":"10.5649/JJPHCS1975.25.393","DOIUrl":null,"url":null,"abstract":"As DDS drugs with various drug delivery functions are often prescribed under in conbination with a widerange of concurrent drug therapies, drug information closely related to its clinical usage is required to guarantee the appropriate multiple pharmaceutical functions of DDS drugs: We surveyed the actual concurrent therapy of lipo-PGE1 (Palux® inj. and Liple®), a targeting-type DDS, with various aqueous infusions at both Okayama University Hospital and Fukui Medical School Hospital. The term of the survey, which was done by evaluating the prescription records, and the total number of prescriptions were 14 months and 1, 005 prescriptions, respectively. Lipo-PGE1 was scarcely administered without any concurrently prescribed infusions. Although lipo-PGE1 was mostly diluted with Glucose Injection or Isotonic Sodium Chloride Solution, some electrolyte infusions were also concurrently prescribed with Lipo-PGE1 in some cases. The magnification of the dilution and the administration route seemed to be related each other. The data revealed in this report ave considered to be useful for a clinical usage-based assessment system to obtain further information guaranteeing the drug delivery function of Lipo-PGE1 from both a pharmaceutical and pharmacodynamic viewpoint one word.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"38 1","pages":"393-398"},"PeriodicalIF":0.0000,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Hospital Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5649/JJPHCS1975.25.393","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

As DDS drugs with various drug delivery functions are often prescribed under in conbination with a widerange of concurrent drug therapies, drug information closely related to its clinical usage is required to guarantee the appropriate multiple pharmaceutical functions of DDS drugs: We surveyed the actual concurrent therapy of lipo-PGE1 (Palux® inj. and Liple®), a targeting-type DDS, with various aqueous infusions at both Okayama University Hospital and Fukui Medical School Hospital. The term of the survey, which was done by evaluating the prescription records, and the total number of prescriptions were 14 months and 1, 005 prescriptions, respectively. Lipo-PGE1 was scarcely administered without any concurrently prescribed infusions. Although lipo-PGE1 was mostly diluted with Glucose Injection or Isotonic Sodium Chloride Solution, some electrolyte infusions were also concurrently prescribed with Lipo-PGE1 in some cases. The magnification of the dilution and the administration route seemed to be related each other. The data revealed in this report ave considered to be useful for a clinical usage-based assessment system to obtain further information guaranteeing the drug delivery function of Lipo-PGE1 from both a pharmaceutical and pharmacodynamic viewpoint one word.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
给药系统的临床应用:PGE1在脂质乳状液水溶液输注中的临床应用处方调查。
由于具有多种药物传递功能的DDS药物经常与多种并发药物治疗联合使用,因此需要与其临床使用密切相关的药物信息,以保证DDS药物的多种药物功能合适:我们调查了lipop - pge1 (Palux®inj)的实际并发治疗情况。和Liple®),一种靶向型DDS,在冈山大学医院和福井医学院医院进行各种水输注。调查周期为14个月,总处方数为1005张。lipop - pge1几乎没有同时规定的输注。虽然脂质pge1主要用葡萄糖注射液或等渗氯化钠溶液稀释,但在某些情况下,一些电解质输注也同时使用脂质pge1。稀释的放大程度与给药途径似乎是相互关联的。本报告中揭示的数据被认为对基于临床使用的评估系统有用,从药理学和药效学的角度获得进一步的信息,保证lipop - pge1的给药功能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Assessment and Analysis of the Assessment Criteria for Meta-Analysis Articles:─ Management of Diabetes Pharmacotherapy Based on Meta-Analysis Articles ─ ベネコートBMI-40とBMI-60との苦味マスキング効果の比較 「創薬ボランティアのしおり」,「被験者管理票」の利用と治験コーディネーター業務 Hemodializability of Pimobendan and Its Active Metabolite, UD-CG 212, in Patients with Congestive Heart Failure Undergoing Hemodialysis An Investigation into the Current Management for Patients with Long-Term Withdrawal Periods from Drugs
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1